Tables 2 and 3), our preclinical study additionally suggests that sunitinib plus anti-PD-L1 may be worthy of further investigation in the adjuvant setting for resectable RCC, while the potential for increased drug toxicities should also be considered. Here, CD274 is linked to renal cell carcinoma.